Abstract
Several investigators including ourselves have shown that hydralazine can potentiate the anti-tumour activity of certain agents against murine tumours probably by manipulating tumour blood flow. In order to investigate the effects of administration of hydralazine on systemic and tumour drug concentrations, we have examined the plasma and tissue pharmacokinetics of the recently developed nitrosourea, Tauromustine (TCNU). The effect of hydralazine on glomerular filtration rate (GFR) in mice was also examined using inulin single injection plasma clearance. An active dose of TCNU (30 mg kg-1) was administered intravenously into non-tumour bearing NMRI mice or mice bearing MAC 15A or MAC 26 subcutaneous tumours. Plasma and tissue levels of TCNU were measured by HPLC. Hydralazine significantly increased (P less than .005 in all cases) the AUCs and decreased the plasma clearance of the drug. Inulin plasma clearance was decreased from 0.258 +/- 0.046 ml min-1 to 0.096 +/- 0.017 ml min-1 (a factor of 2.69) after administration of hydralazine. This decrease in GFR would explain the increased plasma half-lives of a renally cleared drug. It is likely that the increased AUC values are partly responsible for the improved anti-tumour activity of TCNU when administered with hydralazine, but the impact of these findings on toxicity needs to be established.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- ALGIRE G. H., LEGALLAIS F. Y. Vascular reactions of normal and malignant tissues in vivo. IV. The effect of peripheral hypotension on transplanted tumors. J Natl Cancer Inst. 1951 Oct;12(2):399–421. [PubMed] [Google Scholar]
- Chaplin D. J., Acker B. The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):579–585. doi: 10.1016/0360-3016(87)90075-7. [DOI] [PubMed] [Google Scholar]
- Double J. A., Ball C. R., Cowen P. N. Transplantation of adenocarcinomas of the colon in mice. J Natl Cancer Inst. 1975 Jan;54(1):271–275. doi: 10.1093/jnci/54.1.271. [DOI] [PubMed] [Google Scholar]
- Double J. A., Bibby M. C., Loadman P. M., Bloomer J. C. Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1355–1360. doi: 10.1016/0277-5379(88)90228-3. [DOI] [PubMed] [Google Scholar]
- Gerretsen M., Quak J. J., Suh J. S., van Walsum M., Meijer C. J., Snow G. B., van Dongen G. A. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG. Br J Cancer. 1991 Jan;63(1):37–44. doi: 10.1038/bjc.1991.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Honess D. J., Bleehen N. M. Effects of two tumor blood flow modifiers, hydralazine and flavone acetic acid, on KHT tumours and normal tissues in mice. Int J Radiat Biol. 1991 Jul-Aug;60(1-2):249–253. doi: 10.1080/09553009114551951. [DOI] [PubMed] [Google Scholar]
- Seidegård J., Grönquist L., Gunnarsson P. O. Metabolism of a novel nitrosourea, tauromustine, in the rat. Biochem Pharmacol. 1990 May 1;39(9):1431–1436. doi: 10.1016/0006-2952(90)90424-j. [DOI] [PubMed] [Google Scholar]
- Siemann D. W. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine. Br J Cancer. 1990 Sep;62(3):348–353. doi: 10.1038/bjc.1990.295. [DOI] [PMC free article] [PubMed] [Google Scholar]